KZA (ASX) PI3K Drugs for Alzheimers

Originally posted by rikki: ↑

that’s right getting the first condition approved for commercial use is rightfully the focus… as James informed over years the first condition is the hardest and there is very good reasons for choosing GBM and staying focussed

we have finite resources and a program that’s currently underway this is and should be the focus - other options with greater risk may well be of interest with greater capital later on

as per the most recent video - “Kazia currently remains an oncology focussed company” - theres your hint ‘currently’ meaning strategically advantageous to remain on the set program atm

steady as she goes - the previous management had massive swings in SP and became a traders delight at the expense of investors GK then said he was off to do ‘not oncology’ and opened Noxopharm - then settling with Kazia for using our compounds heritage in an immuno oncology treatment Veyonda

im not suggesting this will happen but fine with the steady accumulation we have had - and if we can again gain 200% year on year for the next 2 years then we breach $12 a share in a sustainable and practical way without the great pump and dumps of glitzy spruiking

it’s a science based business it should be handled cautiously - there is a casino of shares out there for big swings and potential short term gains - we are deliberately not there - it’s about growing a company with integrity at every level…

FYI - not instantly coming out with a covid offering like thousands of other companies is not missed opportunity it’s selectively choosing integrity and focus - shows we are serious with our current works and not distracted

thinking we should not be cautious fundamentally misinterprets this industry, this company, this specific endeavour in trials and this management and science board - shows a lot reading it wrong at every level.

thank god we have a strategic and level headed management team to steer this important work and company growth through the minefield of possibilities to the diamond that is a meaningful reality.

the next 6 months will be very interesting indeed.

Expand

yes, there is only a limited amount of money available atm in order to proceed with research so we have to rely on others wanting to fund it themselves - in which case we just provide the compound and researches decide when to publish results so we will have no authority to report anything (note these are not trials but in the lab research) .

It's good to have ideas about what can be done but if the $ aren't there to proceed then it's all pie in the sky stuff and the timeframes will blow out - which is what (IMO) caused the problems with the previous iteration of the company (many promises/dreams but nothing was delivered within a reasonable timeframe)